Neuer Start, neuer Risk!!! (Seite 3)
eröffnet am 14.05.16 01:52:48 von
neuester Beitrag 18.08.22 14:24:11 von
neuester Beitrag 18.08.22 14:24:11 von
Beiträge: 100
ID: 1.231.746
ID: 1.231.746
Aufrufe heute: 0
Gesamt: 12.452
Gesamt: 12.452
Aktive User: 0
ISIN: US72941H5090 · WKN: A3EEZB · Symbol: XMP0
1,5540
EUR
+0,65 %
+0,0100 EUR
Letzter Kurs 22.04.24 Tradegate
Werte aus der Branche Gesundheitswesen
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,2800 | +73,21 | |
| 3,2100 | +24,90 | |
| 0,5501 | +18,33 | |
| 0,6080 | +18,06 | |
| 0,6300 | +14,55 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,5925 | -15,36 | |
| 1,5500 | -19,27 | |
| 2,7600 | -20,69 | |
| 0,9102 | -42,03 | |
| 0,7500 | -48,98 |
Beitrag zu dieser Diskussion schreiben
Feedback
Und nicht zu vergessen: die Herren Vorstände haben sich IMMER gut bedient, mit Optionen, Bonusaktien undundund.
Antwort auf Beitrag Nr.: 61.277.877 von freixenetter am 16.08.19 17:45:49Die ganzen letzten Jahre war‘s leider ein Trauerspiel, bis zum Reverse-Split letztens.
Habe hier schon 2006 verkauft (und in Betongold angelegt).
Mit dem Laden hat es einige ganz böse erwischt, Unverbesserliche Fans😩😩😩
Haben Haus und Hof verloren! Die ganz verrückten hatten sogar eine Macropore-Fansite! Dann wurde umbenannt in Cytori Therapeutics, jetzt Plus T.
Habe hier schon 2006 verkauft (und in Betongold angelegt).
Mit dem Laden hat es einige ganz böse erwischt, Unverbesserliche Fans😩😩😩
Haben Haus und Hof verloren! Die ganz verrückten hatten sogar eine Macropore-Fansite! Dann wurde umbenannt in Cytori Therapeutics, jetzt Plus T.
alter schwede …
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
On August 5, 2019, Plus Therapeutics, Inc. (the “Company”) filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation, as amended (the “Amendment”), with the Secretary of State of the State of Delaware to effectuate a one-for-fifty (1:50) reverse stock split (the “Reverse Stock Split”) of its common stock, par value $0.001 per share (the “Common Stock”), without any change to its par value. The Amendment became effective on the filing date. The Reverse Stock Split will be effective for trading purposes as of the commencement of trading on the Nasdaq Capital Market on August 6, 2019. There was no change in the Company’s Nasdaq ticker symbol, “PSTV,” as a result of the Reverse Stock Split. In connection with the Reverse Stock Split, the CUSIP number for the Common Stock has been changed to 72941H400. Upon effectiveness, each 50 shares of issued and outstanding Common Stock were converted into one newly issued and outstanding share of Common Stock. The Company’s 5,000,000 shares of authorized Preferred Stock were not affected by the Reverse Stock Split.
No fractional shares were issued in connection with the Reverse Stock Split. Any fractional shares of Common Stock that would have otherwise resulted from the Reverse Stock Split were rounded up to the nearest whole share. Outstanding equity awards and the shares available for future grant under the Company’s Amended and Restated 2004 Equity Incentive Plan, 2011 Employee Stock Purchase Plan, 2014 Amended and Restated Equity Incentive Plan and 2015 New Employee Incentive Plan were proportionately reduced (rounded down to the nearest whole share), and the exercise prices of outstanding equity awards were proportionately increased (rounded up to the nearest whole cent) to give effect to the Reverse Stock Split.
A copy of the Amendment is attached to this current report on Form 8-K as Exhibit 3.1, and the above summary is qualified in its entirety by reference to the full text of the Amendment.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
On August 5, 2019, Plus Therapeutics, Inc. (the “Company”) filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation, as amended (the “Amendment”), with the Secretary of State of the State of Delaware to effectuate a one-for-fifty (1:50) reverse stock split (the “Reverse Stock Split”) of its common stock, par value $0.001 per share (the “Common Stock”), without any change to its par value. The Amendment became effective on the filing date. The Reverse Stock Split will be effective for trading purposes as of the commencement of trading on the Nasdaq Capital Market on August 6, 2019. There was no change in the Company’s Nasdaq ticker symbol, “PSTV,” as a result of the Reverse Stock Split. In connection with the Reverse Stock Split, the CUSIP number for the Common Stock has been changed to 72941H400. Upon effectiveness, each 50 shares of issued and outstanding Common Stock were converted into one newly issued and outstanding share of Common Stock. The Company’s 5,000,000 shares of authorized Preferred Stock were not affected by the Reverse Stock Split.
No fractional shares were issued in connection with the Reverse Stock Split. Any fractional shares of Common Stock that would have otherwise resulted from the Reverse Stock Split were rounded up to the nearest whole share. Outstanding equity awards and the shares available for future grant under the Company’s Amended and Restated 2004 Equity Incentive Plan, 2011 Employee Stock Purchase Plan, 2014 Amended and Restated Equity Incentive Plan and 2015 New Employee Incentive Plan were proportionately reduced (rounded down to the nearest whole share), and the exercise prices of outstanding equity awards were proportionately increased (rounded up to the nearest whole cent) to give effect to the Reverse Stock Split.
A copy of the Amendment is attached to this current report on Form 8-K as Exhibit 3.1, and the above summary is qualified in its entirety by reference to the full text of the Amendment.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Antwort auf Beitrag Nr.: 61.072.237 von Shanghai2006 am 21.07.19 02:59:47Was für ein Trauerspiel. Jetzt wird auch noch der Name geändert um neue Opfer f. dieses Spiel anzulocken.
Gruß
Gruß
Zitat von Shanghai2006: Cytori to become Plus Therapeutics
Jul. 16, 2019 4:42 PM ET|About: Cytori Therapeutics, Inc. (CYTX)|By: Douglas W. House, SA News Editor
Citing the need for a new identity to coincide with its new direction, Cytori Therapeutics (NASDAQ:CYTX) will change its name to Plus Therapeutics (PSTV). The change will take effect in several weeks.
The company's initial development focus will be on DocePLUS (formerly ATI-1123), an injectable, albumin-stabilized pegylated liposomal formulation of the chemo agent docetaxel. In other words, the formulation is more stable and longer-acting.
https://seekingalpha.com/news/3478248-cytori-become-plus-the…
Trading Spotlight
Cytori to become Plus Therapeutics
Jul. 16, 2019 4:42 PM ET|About: Cytori Therapeutics, Inc. (CYTX)|By: Douglas W. House, SA News Editor
Citing the need for a new identity to coincide with its new direction, Cytori Therapeutics (NASDAQ:CYTX) will change its name to Plus Therapeutics (PSTV). The change will take effect in several weeks.
The company's initial development focus will be on DocePLUS (formerly ATI-1123), an injectable, albumin-stabilized pegylated liposomal formulation of the chemo agent docetaxel. In other words, the formulation is more stable and longer-acting.
https://seekingalpha.com/news/3478248-cytori-become-plus-the…
Jul. 16, 2019 4:42 PM ET|About: Cytori Therapeutics, Inc. (CYTX)|By: Douglas W. House, SA News Editor
Citing the need for a new identity to coincide with its new direction, Cytori Therapeutics (NASDAQ:CYTX) will change its name to Plus Therapeutics (PSTV). The change will take effect in several weeks.
The company's initial development focus will be on DocePLUS (formerly ATI-1123), an injectable, albumin-stabilized pegylated liposomal formulation of the chemo agent docetaxel. In other words, the formulation is more stable and longer-acting.
https://seekingalpha.com/news/3478248-cytori-become-plus-the…
Cytori Therapeutics Announces Receipt of Puregraft® Royalty Milestone
Oct 30, 2018
SAN DIEGO, Oct. 30, 2018 (GLOBE NEWSWIRE) -- Cytori Therapeutics, Inc. (Nasdaq: CYTX) announced today it has received a milestone payment of $1.0 million from Bimini Technologies, LLC (Bimini). The payment is a result of Bimini achieving the first $10.0 million in gross profits for previous divestiture of the Puregraft® product line.
In 2013, Cytori entered into a Sale and Exclusive License/Supply Agreement with Bimini, pursuant to which Cytori sold to Bimini selected assets relating to Cytori’s Puregraft® product line, a series of standalone fat transplantation products that were developed to improve the predictability of outcomes for autologous fat grafting and aesthetic body contouring.
Bimini may also be obligated to make certain additional milestone payments to Cytori (in an aggregate amount of up to $10.0 million), contingent upon future achievement of certain milestones relating to Bimini’s gross profits from sales of the Puregraft products. The aggregate value of the consideration paid by Bimini to Cytori at the execution of the agreement in July 2013 was $5.0 million.
http://ir.cytori.com/investor-relations/news/news-details/20…
Oct 30, 2018
SAN DIEGO, Oct. 30, 2018 (GLOBE NEWSWIRE) -- Cytori Therapeutics, Inc. (Nasdaq: CYTX) announced today it has received a milestone payment of $1.0 million from Bimini Technologies, LLC (Bimini). The payment is a result of Bimini achieving the first $10.0 million in gross profits for previous divestiture of the Puregraft® product line.
In 2013, Cytori entered into a Sale and Exclusive License/Supply Agreement with Bimini, pursuant to which Cytori sold to Bimini selected assets relating to Cytori’s Puregraft® product line, a series of standalone fat transplantation products that were developed to improve the predictability of outcomes for autologous fat grafting and aesthetic body contouring.
Bimini may also be obligated to make certain additional milestone payments to Cytori (in an aggregate amount of up to $10.0 million), contingent upon future achievement of certain milestones relating to Bimini’s gross profits from sales of the Puregraft products. The aggregate value of the consideration paid by Bimini to Cytori at the execution of the agreement in July 2013 was $5.0 million.
http://ir.cytori.com/investor-relations/news/news-details/20…
A good link for all biotech invested:
https://clinicaltrials.gov/ct2/results
You can save your search, by clicking/marking the save box.
Nice info about recruiting status.
https://clinicaltrials.gov/ct2/results
You can save your search, by clicking/marking the save box.
Nice info about recruiting status.
Cytori Therapeutics, Inc. shares closed up about 46% on nearly 4.3 million shares traded yesterday on no particular news. It was about a week ago that the San Diego-based pharmaceutical company had reported second quarter earnings. For the quarter, Cytori reported a loss of 59 cents per share. This missed analysts' expectations of loss per share of 50 cents. Revenue was $1.6 million. CEO Marc Hedrick said during the earnings call, "Our goal is to be either the first or second generic on the market in Europe. The company also continues to engage and evaluate potential commercial partners for ATI-0918 in Europe, the Middle East, North Africa, North America and Asia Pacific regions. As mentioned before, the global market for this drug is estimated to be approximately $400 million to $750 million annually and in Europe, we estimated an annual market opportunity at approximately $120 million to $300 million." ATI-0918 is the company's lead drug candidate, a generic version of pegylated liposomal encapsulated doxorubicin, which is in Phase III clinical trial and used for various cancer types.
https://finance.yahoo.com/news/today-research-reports-stocks…
https://finance.yahoo.com/news/today-research-reports-stocks…
Cytori Reports Publication of Interim Pilot Data for Cell Therapy in Vocal Fold Scarring
Aug 09, 2018
SAN DIEGO, Aug. 09, 2018 (GLOBE NEWSWIRE) -- Cytori Therapeutics, Inc. (NASDAQ:CYTX) announced publication in the peer-reviewed journal, Stem Cell Research and Therapy, of “Autologous adipose-derived stromal vascular fraction and scarred vocal folds: first clinical case report.” This report describes preliminary data from the CELLCORDES trial of Cytori Cell Therapy™ (ADRCs) in patients with severe voice dysfunction due to scarring of the vocal fold (vocal cords).
The CELLCORDES trial is a fully-enrolled investigator-initiated pilot trial conducted using Cytori Cell Therapy. The trial is being performed by Investigators at the Department of Oto-Rhino-Laryngology and Head and Neck Surgery of Aix-Marseille University and the Cell Therapy Laboratory of La Conception University Hospital, both of Marseille, France. Additional details on the trial may be found at clinicaltrials.gov.
The reported index patient had severe vocal dysfunction persisting for four years following traditional surgery to treat chronic vocal fold lesions. Twelve months after single direct administration with 12 million ADRCs, the patient exhibited improvements in Vocal Handicap Index and other qualitative and quantitative measures of voice quality including: Hirano’s GRB scale (measuring vocal hoarseness, roughness, and breathiness), Jitter (a measure of uncontrolled variation in frequency of the voice), and vocal range. The authors noted that while the remaining seven patients treated in the CELLCORDES study have yet to complete 12-months of follow-up, no serious adverse events have been reported in any subject and no subject has reported worsening of vocal function. Furthermore, three are exhibiting “very good results (especially on the VHI)”.
http://ir.cytori.com/investor-relations/news/news-details/20…
Aug 09, 2018
SAN DIEGO, Aug. 09, 2018 (GLOBE NEWSWIRE) -- Cytori Therapeutics, Inc. (NASDAQ:CYTX) announced publication in the peer-reviewed journal, Stem Cell Research and Therapy, of “Autologous adipose-derived stromal vascular fraction and scarred vocal folds: first clinical case report.” This report describes preliminary data from the CELLCORDES trial of Cytori Cell Therapy™ (ADRCs) in patients with severe voice dysfunction due to scarring of the vocal fold (vocal cords).
The CELLCORDES trial is a fully-enrolled investigator-initiated pilot trial conducted using Cytori Cell Therapy. The trial is being performed by Investigators at the Department of Oto-Rhino-Laryngology and Head and Neck Surgery of Aix-Marseille University and the Cell Therapy Laboratory of La Conception University Hospital, both of Marseille, France. Additional details on the trial may be found at clinicaltrials.gov.
The reported index patient had severe vocal dysfunction persisting for four years following traditional surgery to treat chronic vocal fold lesions. Twelve months after single direct administration with 12 million ADRCs, the patient exhibited improvements in Vocal Handicap Index and other qualitative and quantitative measures of voice quality including: Hirano’s GRB scale (measuring vocal hoarseness, roughness, and breathiness), Jitter (a measure of uncontrolled variation in frequency of the voice), and vocal range. The authors noted that while the remaining seven patients treated in the CELLCORDES study have yet to complete 12-months of follow-up, no serious adverse events have been reported in any subject and no subject has reported worsening of vocal function. Furthermore, three are exhibiting “very good results (especially on the VHI)”.
http://ir.cytori.com/investor-relations/news/news-details/20…
Durchsuchen
Neuer Start, neuer Risk!!!
